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The late-infantile–onset forms are the most genetically heterogeneous group among the autosomal recessively inherited
neurodegenerative disorders, the neuronal ceroid lipofuscinoses (NCLs). The Turkish variant was initially considered to
be a distinct genetic entity, with clinical presentation similar to that of other forms of late-infantile–onset NCL (LINCL),
including age at onset from 2 to 7 years, epileptic seizures, psychomotor deterioration, myoclonus, loss of vision, and
premature death. However, Turkish variant LINCL was recently found to be genetically heterogeneous, because mutations
in two genes, CLN6 and CLN8, were identified to underlie the disease phenotype in a subset of patients. After a ge-
nomewide scan with single-nucleotide–polymorphism markers and homozygosity mapping in nine Turkish families and
one Indian family, not linked to any of the known NCL loci, we mapped a novel variant LINCL locus to chromosome
4q28.1-q28.2 in five families. We identified six different mutations in the MFSD8 gene (previously denoted “MGC33302”),
which encodes a novel polytopic 518–amino acid membrane protein that belongs to the major facilitator superfamily
of transporter proteins. MFSD8 is expressed ubiquitously, with several alternatively spliced variants. Like the majority of
the previously identified NCL proteins, MFSD8 localizes mainly to the lysosomal compartment. However, the function
of MFSD8 remains to be elucidated. Analysis of the genome-scan data suggests the existence of at least three more genes
in the remaining five families, further corroborating the great genetic heterogeneity of LINCLs.
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The neuronal ceroid lipofuscinoses (NCLs) are a group of
autosomal recessive neurodegenerative lysosomal storage
disorders characterized by the accumulation of autofluo-
rescent storage material in many cell types, including neu-
rons.1 Clinically, they present with a variable age at onset,
epileptic seizures, progressive psychomotor decline, visual
failure, and premature death.2 To date, 10 different forms
of human NCLs and seven causative genes (PPT1/CLN1
[MIM 600722], TPP1/CLN2 [MIM 607998], CLN3 [MIM
607042], CLN5 [MIM 608102], CLN6 [MIM 606725], CLN8
[MIM 607837], and CTSD/CLN10 [MIM 116840]) have
been identified.3–11 The loci and genes for adult-onset NCL
(CLN4 [MIM 204300]),12 the Turkish variant (CLN7) late-
infantile–onset NCL (LINCL),13 and the recently identified
CLN9-variant LINCL (MIM 609055)14 have remained un-
detected. Within the NCLs, the late-infantile–onset group
is genetically the most heterogeneous, with causative
mutations found in CLN1, CLN2, CLN5, CLN6, and
CLN8.5,6,8,9,15–17
The phenotype of approximately half of the Turkish pa-
tients with NCL is classified as variant LINCL (vLINCL),
with clinical presentation similar to the other forms of
vLINCL.18 The age at onset ranges from 2 to 7 years, and,
in most patients, onset has been considered to be some-
what later than in the classical LINCL (CLN2 [MIM
204500]).18 The initial symptom is most commonly epi-
leptic seizures, but motor, visual, and speech impairment,
as well as developmental regression with ataxia, may also
be presenting symptoms. The course of seizures is usually
more severe than in classical LINCL. With time, progres-
sive cognitive and motor deterioration, myoclonus, per-
sonality changes, and loss of vision develop, leading to
premature death.18,19 On electron microscopic analysis,
Turkish patients with vLINCL have shown condensed fin-
gerprint profiles in circulating lymphocytes.18 Initially,
Turkish vLINCL was considered a distinct clinical and ge-
netic entity,13 but it has turned out to be genetically het-
erogeneous. We recently reported four mutations in the
CLN8 gene and two mutations in the CLN6 gene account-
ing for the disease in a subset of Turkish patients with
vLINCL.16,20 However, in most patients, the phenotype is
not linked to any of the known NCL genes.
We here describe the identification and initial charac-
terization of a novel gene, major facilitator superfamily
(MFS) domain containing 8 (MFSD8), for Turkish vLINCL.
The gene was identified after homozygosity mapping with
a panel of 10 families, for which we had excluded, by
haplotype analysis, all known human NCL loci as well as
two loci homologous for genes causing NCL-like pheno-
types in animal models (CLCN3 [MIM 600580]21,22 and
CLCN7 [MIM 602727]23).
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Material and Methods
Patients, Controls, and Samples
Nine Turkish families with vLINCL (a, b, c, d, e, f, g, h, and l),
one family of Turkish-Georgian origin (k), and one family of In-
dian origin (j), altogether comprising 13 patients, 21 parents, and
five unaffected siblings, were analyzed. All families except one (j)
were consanguineous. The clinical phenotypes of eight patients
were described elsewhere (patients 17, 18, 22, 24, 25, 27, 28, and
29 in the study by Topcu et al.18). The corresponding patient codes
in the present study are e3, a3, f3, b3, c3, d4, d3, and g3,
respectively.
Patient e5 (the brother of e3) presented at age 3.5 years with
a history of delayed speech development, ataxia since age 2.5
years, and stereotyped hand movements. Brain magnetic reso-
nance imaging (MRI) showed cerebellar and cerebral atrophy and
increased signal intensity in white matter. At age 5 years, he had
prominent myoclonic seizures and rare nocturnal seizures that
responded well to treatment with levetiracetam and intravenous
immunoglobulin. Electroencephalogram (EEG) showed slow
background activity and multifocal epileptic discharges. Eye
ground examination showed retinopathy and optic atrophy. At
age 6 years, he could not walk without support. For the past 6
mo, he has been wheelchair bound and unable to speak.
Patient h3 presented at age 5.5 years with a history of delayed
speech development, as well as ataxia that had been worsening
over the previous 6 mo, frequent falling, and sleep disorders since
age 3.5 years. On examination at 5.5 years, she had ataxic gait
with abnormal cerebellar tests. She was able to speak slowly. Brain
MRI showed cerebellar atrophy. She is taking sodium valproate
for myoclonic seizures. She has tested negative for MECP2 (MIM
300005) mutations and for cerebral folate deficiency. No vacuoles
were found on analysis of peripheral blood smear.
Patient j3, who was of Indian origin, presented at age 3 years
with a history of mild generalized developmental delay. Over the
previous 3 mo, her gait had become increasingly ataxic, and, on
examination, she walked with a wide-based gait. At age 4 years,
she developed frequent clonic seizures that responded well to
treatment with sodium valproate. A wide range of metabolic in-
vestigations, including enzymologic analysis of PPT1 and TPP1
and molecular analysis of CLN3 and CLN6, were normal. MRI of
the brain showed mild cerebellar atrophy and evidence of delayed
white matter maturation. A rectal biopsy showed neuronal cur-
vilinear bodies. She had progressive neurological decline and, by
age 6 years, was wheelchair bound and had limited communi-
cation, significant visual impairment, and frequent breakthrough
seizures. At age 7 years, she developed treatment-resistant status
epilepticus. She died just before her 8th birthday.
Patient k3, who was of Turkish-Georgian origin, presented at
age 8 years with a history of delayed psychomotor development
(she walked at age 2.5 years, spoke at age 3 years, and did not
learn to read). She showed cognitive deterioration, occasional
agitation (with a few hospitalizations in a psychiatric unit), loss
of vision, and walking difficulties. At age 22 years, she was agi-
tated, she had axial akinesia, hypertonia, palilalia, and blindness.
She developed problems with swallowing. Peripheral blood lym-
phocytes showed vacuoles, and a skin biopsy revealed vacuoles
with fingerprint profiles.
Patient l3 presented at age 2 years with a 6-wk history of ataxia
and myoclonic and atonic seizures that responded well to treat-
ment with sodium valproate. Psychomotor development, retinal
examination, and MRI were normal, whereas EEG showed occip-
ital spikes. An axillary skin biopsy showed fingerprint profiles.
Genomic DNA was extracted using standard techniques from
EDTA blood samples collected after informed consent was ob-
tained. The control panel for the identified MFSD8 mutations
consisted of 212 Turkish and 92 Centre d’Etude du Polymorph-
isme Humain (CEPH) chromosomes. RNA for the analysis of a
splice-site mutation was extracted from peripheral blood samples
and for the analysis of the alternative splicing pattern of MFSD8,
from a control fibroblast cell line. An institutional review board
of the Helsinki University Central Hospital approved the study.
Candidate-Locus and Genomewide SNP-Scan Analyses
The previously known NCL loci (CLN1, CLN2, CLN3, CLN5,
CLN6, CLN8, CLN10, CLCN3, and CLCN7) were excluded by mi-
crosatellite analysis, as described elsewhere.20 Four microsatellite
markers (D4S427, D4S2975, D4S2938, and D4S429) spanning∼6.5
cM (according to the Marshfield Genetic Map in the Mammalian
Genotyping Service) were genotyped around the novel CLN7
locus.
Ten families with vLINCL (a, b, c, d, e, f, g, j, l, and k) were
included in the genomewide SNP scan. One affected individual
was genotyped from each family, except from one pedigree (d)
that had four individuals (two affected and two unaffected sib-
lings) genotyped. The SNP scan was performed using Affymetrix’s
GeneChip Human Mapping 50K Xba 240 arrays in accordance
with the manufacturer’s instructions. SNPs were merged with the
Rutgers map24 by their physical locations (NCBI build 35). Inter-
val-specific interpolation was performed. From a total of 58,960
SNPs, the ones without chromosome numbers and physical lo-
cation (466) or with zero heterozygosity values or male hetero-
zygotes on chromosome X (3,904) were removed. Because the
sample size in this data set was too small to calculate SNP het-
erozygosity values, the values from the Affymetrix white sample
were used. Since linkage disequilibrium between markers can
cause false-positive results when both parents are not geno-
typed,25 we selected markers for linkage analysis instead of using
all of them. We did this by grouping the remaining 54,590 SNPs
into clusters, with at least 0.1 cM between the clusters. One SNP
with the largest heterozygosity value was chosen from each clus-
ter, resulting in the use of 8,704 SNPs. The computer program
Merlin (version 1.0.1) was used for multipoint homozygosity
mapping.26 The disease-allele frequency was set at 0.0001, with
penetrances of 0, 0, and 1 for an autosomal recessive model.
Gene Identification and Mutation Analysis
The gene content of the ∼19.5-Mb genomic region between
rs2051785 and rs984369 on chromosome 4q28.1-q28.2 was ex-
amined with the NCBI Map Viewer, build 35.1. Positional can-
didate genes were chosen on the basis of the known or putative
functions of the encoded proteins. The exons and the exon-
intron boundaries of the candidate genes were screened for mu-
tations by genomic sequencing. PCR conditions and primer se-
quences are available from the authors on request. Sequencing
of the purified PCR products was performed with an ABI 3730
DNA Analyzer (Applied Biosystems). Controls were screened for
the identified mutations by genomic sequencing.
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Northern Blot and RT-PCR
The tissue expression of MFSD8 was analyzed with Multiple Tissue
Northern Blots (Human, Human Brain II, and Human Brain V
[BD Biosciences Clontech]) with a 559-bp (c.36_594) probe that
was PCR amplified from MFSD8 cDNA (I.M.A.G.E Consortium
cDNA clone ID 527266427 and RZPD clone IRATp970E0532D).
The probe was [32P]-labeled with the Rediprime II Random Prime
Labeling System (Amersham Biosciences) and was hybridized in
accordance with the manufacturer’s protocol (BD Biosciences
Clontech).
For RT-PCR, RNA isolated from blood or from cultured fibro-
blasts was reverse transcribed using M-MLV Reverse Transcriptase
(Promega). The consequence of the c.7542TrA mutation was
analyzed using primers from exons 6 and 11, and the alternative
splicing of MFSD8 in fibroblasts was analyzed using several exonic
primer pairs that covered the entire coding region, as well as
primers specific for various exon-lacking transcripts. The PCR
products were extracted from agarose gels and were sequenced.
Construction of Expression Plasmids and Site-Directed
Mutagenesis
The PCR-amplified ORF of the human MFSD8 cDNA was cloned
in frame into the aminoterminal hemagglutinin (HA) tag con-
taining pAHC expression vector (kindly provided by Prof. T.
Ma¨kela¨, University of Helsinki, Finland), a derivative of pCIneo
(Promega) (HAMFSD8 construct), and into the pcDNA3.1() ex-
pression vector (Invitrogen), into which a carboxylterminal HA
tag was generated (MFSD8HA construct) by site-directed mutagen-
esis by use of the QuikChange Site-Directed Mutagenesis Kit (Stra-
tagene). Two nucleotide changes, c.929GrA (p.Gly310Asp) and
c.1286GrA (p.Gly429Asp), corresponding to patient missense
mutations, were introduced into the HAMFSD8 construct by site-
directed mutagenesis. All constructs were verified by sequencing.
In Vitro Translation
In vitro translation was performed with the TnT Quick Coupled
Transcription/Translation System (Promega) and the Canine Pan-
creatic Microsomal Membranes (Promega) by use of the HAMFSD8
and MFSD8HA constructs as templates. The [35S]-labeled transla-
tion products were analyzed on 12% SDS-PAGE gels and were
visualized by autoradiography.
Cell Culture, Transfections, and Immunofluorescence
Analysis
COS-1 and HeLa cells (American Type Culture Collection) were
cultivated in Dulbecco’s modified Eagle’s medium (BioWhittaker)
supplemented with 10% and 5% fetal calf serum (PromoCell),
respectively, penicillin, streptomycin, and 1# GlutaMAX
(Gibco). The cells (1.5– cells) were plated onto 6-well52# 10
plates on coverslips 1 d before transfection and were transfected
with 2 mg of wild-type or missense mutation containing HAMFSD8
or wild-type MFSD8HA constructs per well by use of FuGENE 6
Transfection Reagent (Roche). At 18 h after transfection, cells were
incubated with cycloheximide for 2 h, were fixed with 4% par-
aformaldehyde, and were permeabilized either with 0.1% Triton
X-100 in PBS or with 0.2% saponin in PBS supplemented with
0.5% BSA. Overexpressed proteins were detected using mouse
monoclonal or rabbit polyclonal anti-HA antibodies (clones
16B12 [Covance Research Products] and Y-11 [Santa Cruz Bio-
technology], respectively). Antibodies used as organelle markers
were mouse monoclonal anti-early endosome antigen 1 (EEA1
[BD Biosciences]), rabbit polyclonal anti-cathepsin D (CTSD
[DAKO]), rabbit polyclonal anti-giantin (BioSite), mouse mono-
clonal anti–lysosomal–associated membrane protein 1 (Lamp-1,
H4A3 [developed by J. T. August and J. E. K. Hildreth and obtained
from the Developmental Studies Hybridoma Bank, developed un-
der the auspices of the National Institute of Child Health and
Human Development and maintained by The University of Iowa,
Department of Biological Sciences, Iowa City]), mouse monoclo-
nal anti-lysobisphosphatidic acid (LBPA, 6C4 [kindly provided by
Professor Jean Gruenberg, University of Geneva, Switzerland]),
mouse monoclonal anti–mannose-6-phosphate receptor 46
(MPR46 [kindly provided by Professor Kurt von Figura, Go¨ttingen,
Germany]), and mouse monoclonal anti–protein-disulfide isom-
erase (PDI [Stressgen]). Cy2- or Cy3-conjugated secondary anti-
bodies (Jackson ImmunoResearch) were used to visualize the pri-
mary antibodies. The cells were viewed using an Axioplan 2
microscope and were photographed with AxioVision 3.1 (Zeiss).
Bioinformatics
Alternatively spliced transcripts were identified using NCBI
AceView. The topology of MFSD8 was predicted using HMMTOP,
TMHMM, and TMpred prediction programs. Protein domains
were searched for in the Pfam 20.0 database. Proteins homologous
and similar to MFSD8 were searched for by NCBI protein-protein
BLAST. The peptide sequences were aligned using MAFFT version
5.8.
Results
Genomewide SNP Scan and Homozygosity Mapping
Analysis of genomewide SNP-scan data in 10 families with
vLINCL—for which we had excluded all known NCL loci
either elsewhere20 or in this study (data not shown) (see
the “Material and Methods” section)—revealed three
regions, on chromosomes 4, 8, and 15, with heterozygos-
ity LOD (HLOD) scores 12 (see the tab-delimited ASCII
file, which can be imported into a spreadsheet, of data set
1 [online only]). Six families (a, b, c, e, f, and j) contributed
to the highest HLOD score of 3.39 at SNP rs348085 on
chromosome 4q28.1-q28.2, where an ∼19.5-Mb region
(from rs7657655 to rs10518621) of overlapping homo-
zygosity was detected in all but one of these families. In
family a, the homozygous region was !1 Mb, which was
considered to be too short to reflect a region homozygous
by descent, considering the close consanguinity. The hap-
lotypes across the region were different in each family
(data not shown). Four families (d, e, g, and l) contributed
to the HLOD score of 2.48 on chromosome 15 (at SNP
rs2956147). Four families (b, c, e, and l) contributed to
the HLOD score of 2.05 on chromosome 8 (at SNP
rs2432960). We decided to first focus on the ∼19.5-Mb
region on chromosome 4 because it had the strongest evi-
dence for linkage. Genotyping four microsatellite markers
(D4S427, D4S2975, D4S2938, and D4S429) in patients in
families b, c, e, f, and j and in an additional family (h)
did not narrow the region but revealed that the patient
in family h also is homozygous for these markers.
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Table 1. MFSD8 Mutations Identified in the Present Study
Nucleotide
Change








Topcu et al.18) Origin
c.697ArG p.Arg233Gly or splicing effect Exon 7 f3 (22) Turkey
c.7542TrA Altered splicing Intron 8 e3 (17) and e5 Turkey
c.894TrG p.Tyr298X Exon 10 j3 India
c.929GrA p.Gly310Asp Exon 10 c3 (25) Turkey
c.1102GrC p.Asp368His or splicing effect Exon 11 h3 Turkey
c.1286GrA p.Gly429Asp Exon 12 b3 (24) Turkey
Identification of Mutations in MFSD8 Underlying vLINCL
Within the critical region of ∼19.5 Mb, we identified at
least 90 known or putative genes. After excluding two of
the genes (TRAM1L1 and TRPC3 [MIM 602345]) by se-
quencing, we identified six homozygous mutations (ta-
ble 1 and fig. 1) in MFSD8 (a HUGO Gene Nomencla-
ture Committee–approved symbol; previously denoted
“MGC33302”; GenBank accession number NM_152778),
by screening the 12 protein-coding exons (exons 2–13) of
the gene. All six mutations cosegregated with the disease
phenotype in the respective families and were not found
in 212 Turkish and 92 CEPH control chromosomes.
Patient j3 was homozygous for nonsense mutation
c.894TrG in exon 10, which created a premature stop
codon (p.Tyr298X) and was predicted to truncate the pro-
tein by 221 aa. Patients c3 and b3 were homozygous for
missense mutations c.929GrA (p.Gly310Asp) in exon 10
and c.1286GrA (p.Gly429Asp) in exon 12, respectively,
which affect amino acids that are conserved across ver-
tebrates (fig. 2). In two patients, we identified homozygous
nucleotide changes at the exon-intron junctions that may
either change an amino acid or affect the splicing of the
transcript: an ArG transition at the second-to-last nucle-
otide of exon 7 (c.697ArG; p.Arg233Gly) in patient f3,
and a transversion of GrC at the last nucleotide of exon
11 (c.1102GrC; p.Asp368His) in patient h3. Both Arg233
and Asp368 are conserved in vertebrates (fig. 2). The only
intronic mutation detected (c.7542TrA) was identified
in intron 8 in two affected siblings, e3 and e5. An RT-PCR
analysis performed from an RNA sample of patient e5 with
primers from exons 6 and 11 revealed an altered pattern
of PCR products (fig. 1B), implying aberrant splicing of
the mutant transcript. No mutations in MFSD8 were iden-
tified in patients that lacked homozygosity over the CLN7
locus (families a, d, g, k, and l).
MFSD8 mRNA Expression and Alternatively Spliced Variants
In northern-blot analysis of MFSD8 expression, an ∼5-kb
transcript, expressed at very low levels, was detected in all
tissues analyzed (fig. 3). In all brain regions and in lung,
it was the only transcript seen. In other tissues, transcripts
that ranged in size from ∼1 to ∼3 kb and/or ∼6 kb were
also present.
Both northern-blot and EST database analyses support
the ubiquitous expression of the main MFSD8 transcript,
including exons 1–13, whereas the alternatively spliced
variants seem to have more-limited tissue distribution
(NCBI AceView). In particular, four alternative, partial var-
iants were present in EST databases: one lacking exon 2
(BI553701), one lacking exon 7 (BX341359), one lacking
exons 7 and 8 (BG434527), and one lacking exon 11 (rep-
resented by three sequences: BX341358, BG542082, and
BU618424). None of these variants produce full-length in-
frame transcripts. Translation of the variant lacking exon
2 is predicted to start at methionine 46 at exon 3
(p.Met46). The variant lacking both exons 7 and 8 pro-
duces a transcript with an in-frame deletion of 67 aa,
whereas the others lead to frameshifts and premature stop
codons. We verified these and identified several other al-
ternatively spliced transcripts by RT-PCR analyses (data
not shown).
MFSD8 Protein
MFSD8 is predicted to encode a 518-aa protein of ∼58 kDa
with 12 predicted transmembrane domains (fig. 4). Pfam
analysis of the MFSD8 amino acid sequence showed that
it contains an MFS domain (MFS_1) at amino acid posi-
tions p.42_477 and a sugar (and other) transporter domain
(Sugar_tr) at amino acid positions p.72_147. In an in vitro
translation assay, HA-tagged MFSD8 proteins were de-
tected as ∼60-kDa bands on SDS-PAGE (data not shown),
in agreement with the calculated molecular weight of the
protein. In spite of several attempts under various con-
ditions, we were not able to detect soluble overexpressed
HA-MFSD8 in transfected cell lysates on western blot with
the use of HA-antibody, which is likely to be a result of
the predicted excessive hydrophobicity of the protein,
poor transfer of the protein, or partial proteolysis of the
HA tag.
MFSD8 appears to be evolutionarily conserved, since a
BLAST search returned several homologues for MFSD8 in
different species. In each vertebrate species, MFSD8 has a
single orthologue. For instance, mouse and zebrafish or-
thologues are ∼82% and ∼61% identical to the human
protein, respectively (fig. 2). In invertebrates, several
weakly similar proteins (∼18%–35% of amino acids are
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Figure 1. MFSD8-associated mutations. A, Sequence chromatograms showing homozygous MFSD8 mutations in six patients with vLINCL
(f3, e3, j3, c3, h3, and b3) and the respective control (c) sequences. The mutated bases are underlined, and the vertical lines indicate
exon-intron boundaries. B, Aberrant splicing of the c.7542TrA mutant transcript. The agarose gel shows the mRNA splicing pattern
in patient e5 (A/A), who is homozygous for c.7542TrA, in his heterozygous carrier mother (T/A), and in a control individual (T/T),
analyzed by RT-PCR with primers from exons 6 and 11. In the sample from patient e5, an altered pattern of PCR products is seen, with
almost complete lack of the normal transcript (∼550 bp) containing exons 7–10, a complete lack of an alternatively spliced variant
lacking exon 7 (D7) (∼400 bp), and increased expression of two alternatively spliced variants: one lacking exon 8 (D8) (∼500 bp) and
one lacking exons 7 and 8 (D78) (∼350 bp). In addition, a faint band of ∼480 bp, the sequence of which remains unknown, is visible
in the samples from patient e5 and his mother. The positions of the 100-bp ladder-size marker are shown on the left.
identical to those in human MFSD8) were identified: 2 in
Drosophila melanogaster, 18 in Caenorhabditis elegans, and
4 in Saccharomyces cerevisiae.
Intracellular Localization of MFSD8
To study the subcellular localization of MFSD8, we tran-
siently overexpressed the HAMFSD8 construct in COS-1
cells and, by using HA antibodies in immunofluorescence
analysis, detected the protein in punctate structures in the
cytoplasm (fig. 5A, 5D, and 5G). This staining pattern was
confirmed by overexpressing MFSD8HA in COS-1 cells and
also by transfecting HeLa cells with both constructs (data
not shown). A variety of organelle markers were used to
identify the MFSD8-positive punctate cytoplasmic struc-
tures in COS-1 cells. The HA-MFSD8 protein displayed the
strongest overlap with lysosomal markers Lamp-1 (fig. 5A–
5C), CTSD, and LBPA (data not shown). No overlap was
observed with early endosomal protein EEA1 (fig. 5D–5F)
or with markers used to visualize the compartments of the
early secretory pathway, including endoplasmic reticulum
(ER) resident PDI, Golgi protein giantin (data not shown),
and trans-Golgi network protein MPR46 (fig. 5G–5I). Pa-
tient missense mutations p.Gly310Asp and p.Gly429Asp,
which were introduced into the wild-type MFSD8, did not
interfere with the lysosomal localization of the HA-MFSD8
protein in transiently transfected COS-1 cells (fig. 5J–5O).
Discussion
In this article, we describe the mapping, identification,
and initial characterization of a novel NCL gene. Because
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Figure 2. Conservation of the MFSD8 amino acid sequence among human (Homo sapiens), mouse (Mus musculus), and zebrafish (Danio
rerio). Amino acid sequences were aligned using MAFFT version 5.8. The amino acid numbering is indicated for the human polypeptide.
Identical amino acids are indicated with gray shading. Sites of exonic disease-causing mutations are marked with an asterisk (*):
p.Arg233Gly/splice, p.Tyr298X, p.Gly310Asp, p.Asp368His/splice, and p.Gly429Asp. The predicted 12 transmembrane domains are in-
dicated with boxes and Roman numerals.
the identification of this gene was mainly based on Turk-
ish families with vLINCL, we denoted the linked locus as
CLN7, the long-sought locus for Turkish vLINCL. Given
that all families except one were consanguineous, we as-
sumed that the chromosomal region harboring the disease
gene would be identical by decent in most families. We
therefore used a SNP-based homozygosity mapping ap-
proach28 with 10 families, to localize the disease gene. In
line with our assumption, we identified a region on chro-
mosome 4 with statistically significant linkage, with five
families showing large overlapping regions of homozy-
gosity, reflecting identity by descent. However, the hap-
lotypes were different between families, suggesting the oc-
currence of a private mutation in each family.
Consequently, we identified six nucleotide changes in
MFSD8, one in each of the six families. These are likely to
be disease-causing, because they altered the predicted
amino acid composition of the MFSD8 protein. It is not
known whether the only nonsense mutation identified
(p.Tyr298X) results in a truncated protein that is non-
functional or leads to degradation of the mRNA through
nonsense-mediated decay.29 The two identified missense
mutations (p.Gly310Asp and p.Gly429Asp) change the
highly conserved glycines that reside in the predicted 8th
and 10th transmembrane domains, respectively, to aspar-
tic acids (figs. 2 and 4). These changes do not, however,
alter the localization of the protein, as shown by immu-
nofluorescence staining of the overexpressed mutant HA-
tagged proteins. This suggests that the primary defect of
these mutants is more likely the result of the functional
properties of the mutated protein than the result of altered
localization. Two of the mutations (c.697ArG and
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Figure 3. Northern-blot analysis of MFSD8 expression. An ∼5-kb MFSD8 transcript (upper panels) was detected in all tissues analyzed.
In all brain regions and in lung, it is the only transcript seen. In other tissues, transcripts that ranged in size from ∼1 to ∼3 kb and/
or ∼6 kb were also present. Lower panels, Hybridization with human b-actin cDNA as a control for RNA loading. The positions of size
markers are shown on the left of each blot.
Figure 4. Schematic structure of the MFSD8 protein, with po-
sitions of patient mutations that affect exonic sequences. MFSD8
is predicted to contain 12 transmembrane domains, according to
the prediction programs HMMTOP, TMHMM, and TMpred. The site
of the nonsense mutation (p.Tyr298X) is indicated with a square,
the site of the missense mutations (p.Gly310Asp and p.Gly429Asp)
with circles, and the site of mutations that either change amino
acids or affect splicing (p.Arg233Gly/splice and p.Asp368His/
splice) with crosses.
c.1102GrC) may change highly conserved amino acids
(p.Arg233Gly and p.Asp368His, respectively) and may re-
sult in changes in the protein structure and/or function.
Alternatively, they may affect the splicing of the tran-
script, because they change sequences at the exon-intron
junctions in the 3′ ends of exons 7 and 11 and thus may
lead to the production of abnormal mRNAs and/or pro-
teins.30 Because of the unavailability of RNA samples from
patients with these mutations, we were not able to test
the outcome of these changes at the mRNA level. How-
ever, RNA was available from the patient with the intronic
c.7542TrA mutation that affects the donor-splice site of
intron 8. In RT-PCR analysis, we showed that the mutation
results in an altered splicing pattern. This is expected,
since a nucleotide change at the nearly invariant second
thymine at the 5′ end of an intron usually leads to inac-
curate recognition of exon-intron boundaries and to dis-
turbed splicing.30
MFSD8 is ubiquitously expressed, with the main tran-
script of ∼5 kb being the only one present in the brain.
In addition, the EST and RT-PCR data suggest that MFSD8
shows a complex pattern of alternative splicing. The func-
tional relevance of the alternative transcripts seen in
northern-blot analysis and the less abundant transcripts,
represented only by one or few ESTs, is not known, but
some of them may reflect a posttranscriptional mecha-
nism for regulation of MFSD8 expression.31 MFSD8 is pre-
dicted to be a polytopic integral membrane protein with
12 membrane-spanning domains (fig. 4). In immunofluo-
rescence analysis, MFSD8 was shown to colocalize with
lysosomal markers, implying that it is a novel integral
lysosomal membrane protein. The majority of the previ-
ously identified NCL proteins show lysosomal localiza-
tion—CTSD, PPT1, and TPP1 encode soluble lysosomal
enzymes,4,5,32–35 whereas CLN3 and CLN5 code for lyso-
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Figure 5. Lysosomal localization of both wild-type and mutant MFSD8 proteins. Subcellular localization of HA-tagged wild-type (wt)
and mutant (G310D and G429D) MFSD8 was seen in transiently transfected COS-1 cells. A, D, and G, Distribution of the HA-MFSD8
protein by use of an antibody against HA (red). B, Lysosomal staining pattern by use of an anti–Lamp-1 antibody (green). C, Overlay
of the HA-MFSD8 and Lamp-1 stainings. E, Early endosomal staining pattern by use of an anti-EEA1 antibody (green). F, Overlay of the
HA-MFSD8 and EEA1 stainings. H, Trans-Golgi-network staining pattern by use of an anti-MPR46 antibody (green). I, Overlay of the
HA-MFSD8 and MPR46 stainings. J and M, Distribution of the G310D mutant (J) and the G429D mutant (M) HA-MFSD8 proteins by use
of an antibody against HA (red). K and N, Lysosomal staining pattern by use of an anti–Lamp-1 antibody (green). L and O, Overlays
of the mutant HA-MFSD8 and Lamp-1 stainings. Yellow indicates overlap of wild-type or mutant HA-MFSD8 and the subcellular markers.
Scale bars (10 mm) are shown in panels C, F, I, L, and O.
somal proteins of unknown function.3,6,36,37 On the con-
trary, two NCL proteins localize either exclusively to the
ER (CLN6)38,39 or to both the ER and the ER-Golgi inter-
mediate compartment (CLN8).40
On the basis of homology analyses, MFSD8 belongs to
the MFS of proteins. The MFS is a very large family of
proteins present ubiquitously in all classes of organisms.41
These proteins are single-polypeptide carriers that are able
to transport small solutes by using chemiosmotic ion gra-
dients.41 Many of these proteins span the membrane 12
times, as does MFSD8. The MFS proteins are classified into
several phylogenetic subfamilies, and this classification
correlates with the function, each subfamily transporting
a specific class of substrates, including sugars, drugs, in-
organic and organic cations, various metabolites, etc.41 In
humans, the most similar proteins to MFSD8 include MFS
domain containing 9 (MFSD9 or MGC11332) and tetra-
cycline transporter–like protein (TETRAN), which are pre-
dicted to have tetracycline-transporter activities; solute
carrier family 18 member 2 (SLC18A2, also denoted
“VMAT2” [MIM 193001]), which translocates monoam-
ines from cytosol to synaptic vesicles,42 and SLC22A18
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(also denoted “ORCTL2” [MIM 602631]), which acts in
transport of organic cations.43 MFSD8 is conserved in ver-
tebrates with a single identifiable orthologue, but similar
proteins are identified also in invertebrates. In S. cerevisiae,
the most similar proteins to MFSD8 are Jen1p, Git1p,
Ykr105cp, and Ycr023cp, which all belong to the MFS.
Jen1p is a functional lactate transporter,44,45 whereas
Git1p mediates uptake of glycerophosphoinositol and
glycerophosphocholine.46,47 In D. melanogaster, the most
similar proteins to MFSD8 are CG8596-PA, which has an
unknown function, and a tetracycline-resistance protein
CG5760-PA, both belonging to the MFS (FlyBase). In C.
elegans, there are several proteins similar to MFSD8, most
of which belong to the MFS and many of which have
protein domains involved in transport processes (Worm-
Base). Being a member of the MFS, MFSD8 is likely to
function as a transporter. However, the substrate specific-
ity of MFSD8 remains to be elucidated.
When first described, Turkish vLINCL was considered a
distinct clinical and genetic entity.13 However, it is now
evident that, even if the clinical phenotype is quite uni-
form, Turkish vLINCL is genetically very heterogeneous,
with mutations identified already in three genes, CLN6,20
CLN8,16 and MFSD8. In the remaining five Turkish fami-
lies—for which we excluded the currently known NCL
genes, including CLCN6 (MIM 602726) and CTSF (MIM
603539), homologues of which were recently reported to
cause NCL-like phenotypes in mice48,49—the SNP-scan
data imply the presence of at least three more underlying
genes. This further corroborates the great heterogeneity
of Turkish vLINCL. Identification and characterization of
the MFSD8 gene and further dissection of the genetic back-
ground of Turkish vLINCL will be important steps toward
complete understanding of the genetic spectrum of the
NCLs and, additionally, toward understanding their un-
derlying molecular mechanisms.
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